Hematologic Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Questions Remain With CAR-T's, Checkpoints in Hematologic Malignancies - OncLive



OncLive
 
Questions Remain With CAR-T's, Checkpoints in Hematologic Malignancies 
OncLive
OncLive: There have a handful of recent FDA approvals and encouraging clinical trial results across the field of hematologic cancers. What is most notable to mention? Gordon: In the beginning [of the conference], Dr Olga Frankfurt spoke about acute ...

 


Presents: Pre-Conference Perspectives on Hematologic Malignancies - Business Wire (press release)



Presents: Pre-Conference Perspectives on Hematologic Malignancies 
Business Wire (press release)
CRANBURY, N.J.--(BUSINESS WIRE)--OncLiveŽ, a leading digital provider of resources and information to oncology professionals, will host a live webinar, entitled ?Pre-Conference Perspectives on Hematologic Malignancies.? The exclusive broadcast ...

and more » 


Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of ... - Markets Insider



Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of ... 
Markets Insider
"Our data presentations at this year's ASH Annual Meeting underscore our continued commitment to patients and deep expertise in researching hematologic malignancies across various difficult-to-treat blood cancers," said Gary Gordon, M.D., Ph.D., vice ...

and more » 


TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and FludaraŽ in Patients with ... - GlobeNewswire (press release)



TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and FludaraŽ in Patients with ... 
GlobeNewswire (press release)
SAN DIEGO, Nov. 13, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related ...
TRACON's TRC102 shows positive action in early-stage blood cancer study; shares ahead 23% after hours Seeking Alpha

all 2 news articles » 


First Tx for Erdheim-Chester Disease, a Rare Blood Cancer - Medscape



Medscape
 
First Tx for Erdheim-Chester Disease, a Rare Blood Cancer 
Medscape
The US Food and Drug Administration (FDA) has approved a treatment for the first time for use in patients with Erdheim-Chester disease (ECD), a rare hematologic malignancy affecting about 600 to 700 patients worldwide. These patients have very limited ...
FDA Approves Vemurafenib for Erdheim-Chester Disease Cancer Therapy Advisor
FDA Approves First Treatment for Erdheim-Chester Disease Pharmacy Practice News

all 55 news articles » 


Celyad Announces Third Quarter 2017 Business Update - GlobeNewswire (press release)



Celyad Announces Third Quarter 2017 Business Update 
GlobeNewswire (press release)
At the first dose-level, 3x108, CYAD-01 T-cells were administered without any prior conditioning chemotherapy to a cohort of three patients with hematologic cancer (two with AML and one with multiple myeloma): One AML patient achieved a MLFS ...

and more » 


Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities - AJMC.com Managed Markets Network



Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities 
AJMC.com Managed Markets Network
The treatment with PARP inhibitors (PARPis) olaparib, veliparib, and niraparib is related to the increasing risk of hematologic toxicities in cancer patients, including neutropenia, thrombocytopenia, and anemia, and a new study has reported that ...

 


Acalabrutinib MCL Approval Raises Sequencing Questions - OncLive



OncLive
 
Acalabrutinib MCL Approval Raises Sequencing Questions 
OncLive
The October 2017 FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL) added another BTK inhibitor to the armamentarium while contributing to the growing discussion of sequencing with other available agents, explained ...

 


OncoBreak: 'Am I a Survivor?' T-Cell Therapy Expands; Bogus Breast Screening - MedPage Today



OncoBreak: 'Am I a Survivor?' T-Cell Therapy Expands; Bogus Breast Screening 
MedPage Today
An oncologist offers personal and professional insights into the possible answers. (ASCO Connection). Clinical investigation of adoptive T-cell therapy (CAR T) quickly expanded beyond hematologic cancers to solid tumors. (Roswell Park Cancer Institute).

and more » 


Caris Life Sciences Files Patent Infringement Suit vs. Foundation Medicine - Genetic Engineering & Biotechnology News (blog)



Caris Life Sciences Files Patent Infringement Suit vs. Foundation Medicine 
Genetic Engineering & Biotechnology News (blog)
Both assays are designed to interrogate hundreds of cancer-related genes in solid tumors, or hematologic cancers and advanced sarcomas, respectively, to identify genomic alterations in patients that can be matched with a therapy that targets them.

and more »